Pembrolizumab and bevacizumab for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (specific types only).
- Your cancer is platinum-sensitive or platinum-resistant, and you have had no more than 4 prior treatment “lines” (some maintenance treatments don’t count as extra lines).
- Your overall health is good enough for treatment (ECOG 0–1) and you have measurable tumors on scans.
- You can have enough blood and organ function for treatment (blood counts, kidney function, liver tests, and albumin meeting the study limits).
- You must be willing to get a tumor biopsy before starting and again after about 3 cycles (if possible).
- You cannot be “platinum-refractory,” and you must not have certain recent treatments or conditions (like recent immunotherapy, untreated brain metastases, or serious uncontrolled infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
This Phase 1/2 trial tests a new cancer vaccine therapy combined with pembrolizumab (an immunotherapy) to treat advanced, recurrent ovarian, fallopian tube, or primary peritoneal cancer. It may help your immune system recognize and attack the cancer, especially if your tumor has a specific target called FRα.
This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.
This trial compares a combination of two drugs (sacituzumab govitecan and bevacizumab) to standard chemotherapy for ovarian cancer that has come back after treatment with a PARP inhibitor. It is for people whose cancer has a BRCA mutation or is homologous recombination deficient.
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
Hear when a new Recurrent Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.